Life Biosciences Reports First ER-100 Clinical Data

Sharon Rosenzweig-Lipson, PhD, discusses preliminary safety and visual field findings from the first 3 participants in a trial of epigenetic restoration therapy for optic neuropathies.

By: Sharon Rosenzweig-Lipson, PhD

Glaucoma Physician October 12, 2026

Clinical Scorecard: Life Biosciences Reports First ER-100 Clinical Data

At a Glance

Category	Detail
Condition	Clinical topic addressed by the source article: Life Biosciences Reports First ER-100 Clinical Data
Key Mechanisms	Mechanisms or clinical associations described in the source article.
Target Population	Patients or participants described in the source article.
Care Setting	Clinical trial research in optic neuropathies; preliminary findings from the first 3 participants in the glaucoma cohort at the lowest dose were presented at Eyecelerator at AAO.

Key Highlights

The report presents preliminary data from the first 3 participants in the glaucoma cohort at the lowest ER-100 dose.
ER-100 was reported as well tolerated in these participants.
No adverse events or dose-limiting toxicities were reported in this initial cohort.
Humphrey visual field testing showed evidence of improvement across a number of points.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

Risks

Patient & Prescribing Data

First 3 participants in the glaucoma cohort treated at the lowest dose of ER-100.

The initial cohort was reported to tolerate ER-100 without adverse events or dose-limiting toxicities. No prescribing or dosing details beyond the lowest-dose cohort are provided.